Department of Cardiology, Guangdong Cardiovascular Institute, Guangdong Academy of Medical Sciences, Guangdong Provincial People's Hospital, Southern Medical University, Guangzhou, China
Auto-generated profile, based on publicly available information
Xuyu He
Department of Cardiology, Guangdong Cardiovascular Institute, Guangdong Academy of Medical Sciences, Guangdong Provincial People's Hospital, Southern Medical University, Guangzhou, China
Radiation-induced brain injury (RIBI) is a common complication of radiotherapy that leads to neurological symptoms, significantly impairing patients' daily functioning and long-term rehabilitation. Consequently, the development of effective therapeutic strategies has received considerable attention. As an emerging approach in the management of neurological disorders, brain-computer interface (BCI) technology shows substantial potential for both the assessment and treatment of RIBI. This review synthesizes evidence retrieved from electronic databases and examines RIBI from the perspectives of its mechanisms and clinical manifestations. Current findings suggest that BCI technology holds promise for several applications in RIBI, including early diagnosis, mitigation of neuroinflammation, alleviation of associated symptoms, and prediction and management of complications. The implementation of BCI is likely to play a significant role in early assessment and treatment processes for RIBI. Furthermore, with ongoing technological advancements, the development of next-generation BCI is expected to enable more targeted treatment that address additional pathological mechanisms of RIBI, thereby progressively improving the quality of life for affected patients.
1 January 2025 in Cardiology Research and Practice
Background: Mild alanine transaminase (ALT) elevation is common in older patients with acute myocardial infarction (AMI), but its prognostic value and implications for statin therapy remain unclear. Methods: This retrospective cohort study included 321 AMI patients aged ≥ 75 years admitted from 2014 to 2019 at Guangdong Provincial People’s Hospital. Mild ALT elevation was defined as ALT between the upper limit of normal (ULN) and 3 × ULN, and significant elevation as ALT > 3 × ULN. Patients were grouped by admission ALT into normal (N, n = 201), mildly elevated (ME, n = 104), and significantly elevated (SE, n = 16). Logistic regression analyses in SPSS 26.0 and R 3.4.3 assessed the association between ALT levels and in‐hospital mortality, adjusting for cardiac function, infarct size, renal function, and treatment factors. Results: Among survivors with elevated ALT, 87.4% achieved normalization before discharge. Statin intolerance was identified in 58 patients (18.9%) at admission and persisted in 6.7% at discharge. The ALT‐ME group had significantly higher statin intolerance (36.5% vs. 2.0%, p < 0.001) and higher in‐hospital mortality (18.3% vs. 6.0%, p = 0.001) compared with the ALT‐N group. Logistic regression analysis demonstrated that ALT elevation was independently associated with higher in‐hospital mortality (per 10 U/L ALT elevation, odds ratio 1.164, p = 0.010). Conclusion: In older patients with AMI, mild elevation in ALT levels upon admission is associated with worse in‐hospital outcomes, and statin intolerance is common and mostly reversible. Short‐term substitutes for statins should be considered in these patients.